The FDA has approved omadacycline, an oral-only dosing regimen, for the treatment of community-acquired bacterial pneumonia, according to a press release from Paratek Pharmaceuticals.Omadacycline (Nuzyra, Paratek Pharmaceuticals) is a novel antibiotic with once-daily oral and IV formulations for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure
Paratek Pharmaceuticals (PRTK) Announces FDA Approval of NUZYRA Oral Only Dosing Regimen for Treatment of CABP streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator
Greetings, and welcome to the Paratek Pharmaceuticals fourth-quarter and full-year 2020 earnings conference call. [Operator instructions] As a reminder, this conference is being recorded. I d now like to turn the conference over to your host, Ben Strain, vice president of investor relations. Please go ahead, sir.
Ben Strain
Vice President of Investor Relations
Good afternoon, and welcome to Paratek s fourth-quarter and full-year 2020 earnings and corporate update conference call. A press release for the company s fourth-quarter and full-year results was issued earlier today, and we ve also posted slides on our website that will be referred to on this call. Both can be found at www.paratekpharma.com. Participants on today s call are Evan Loh, CEO; Adam Woodrow, president and chief commercial officer; Randy Brenner, chief development and regulatory officer; Michael Bigham, executive chairman; and Sarah Higgins, vice president of finance, controller, and principal accoun